证券代码：688317 证券简称：之江生物 公告编号：2026-010 上海之江生物科技股份有限公司 关于自愿披露公司产品获得相关认证的公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海之江生物科技股份有限公司（以下简称"公司"）2 项产品于近期获得 相关认证，现将具体情况公告如下： | 产品名称 | | 认证机构 | 证书编号 | 应用领域 | 有效期 | | --- | --- | --- | --- | --- | --- | | | | Medical | | | | | Viral RNA | Isolation | Device | | | | | Kit | (Preloaded for | Authority | IVDB10400 | 基因组研究、分子生 | 2026 年 3 月 6 日 | | Auto-Extraction) | | Malaysia | 026-22793 | 物学实验室科学和 | 至 2031 年 3 月 5 | | 核酸提取试剂（预装用 | | 马 来 西 亚 | 3 | ...

证券代码：688317 证券简称：之江生物 公告编号：2026-009 上海之江生物科技股份有限公司 关于 2025 年第三次以集中竞价交易方式回购公司股份 的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： | 回购方案首次披露日 | 2025/10/17 | | --- | --- | | 回购方案实施期限 | 2025 年 10 月 15 日~2026 年 10 月 14 日 | | 预计回购金额 | 6,000万元~12,000万元 | | 回购用途 | □减少注册资本 √用于员工持股计划或股权激励 | | | □用于转换公司可转债 | | | □为维护公司价值及股东权益 | | 累计已回购股数 | 206.5434万股 | | 累计已回购股数占总股本比例 | 1.07% | | 累计已回购金额 | 4,448.90万元 | | 实际回购价格区间 | 19.58元/股~23.49元/股 | 一、回购股份的基本情况 2025 年 10 月 15 日，上海之江生物科技股份有限公司（以下简称"公司"） ...

Core Viewpoint - Zhijiang Biology (688317.SH) reported a significant decline in revenue and an increase in net loss for the fiscal year 2025, primarily due to policy changes and market conditions [1] Financial Performance - The company achieved total operating revenue of 124.91 million yuan, a decrease of 30.08% compared to the same period last year [1] - The net profit attributable to the parent company was -34.30 million yuan, representing an increase in loss of 93.16 million yuan year-on-year [1] Factors Affecting Performance - Revenue decline was attributed to the implementation of centralized procurement policies leading to lower sales prices, an increase in the value-added tax rate on self-produced reagent products to 13%, and changes in product sales structure [1] - The decrease in financial income and reduced foreign exchange gains also contributed to the operational losses [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, exploring potential opportunities, and optimizing cost reduction and efficiency improvement measures [1] - Cost control measures have shown effectiveness, with a year-on-year reduction in asset impairment losses, leading to a decrease in operational losses compared to the previous year [1]

Core Viewpoint - Zhijiang Biotech (688317.SH) reported a significant decline in revenue and an increase in net loss for the fiscal year 2025, primarily due to pricing pressures from centralized procurement policies and changes in product sales structure [1] Financial Performance - The company achieved total operating revenue of 124.91 million yuan, a decrease of 30.08% compared to the same period last year [1] - The net profit attributable to the parent company was -34.30 million yuan, representing an increase in loss of 93.16 million yuan year-on-year [1] Factors Affecting Performance - Revenue decline was attributed to the implementation of centralized procurement policies leading to lower sales prices, an increase in the value-added tax rate on self-produced reagent products to 13%, and changes in product sales structure [1] - The decrease in financial income and reduced foreign exchange gains also contributed to the operational losses [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, exploring potential opportunities, and optimizing cost reduction and efficiency improvement measures [1] - Cost control measures have shown effectiveness, with a year-on-year reduction in asset impairment losses, leading to a decrease in operational losses compared to the previous year [1]

Core Viewpoint - Zhijiang Biology reported a significant decline in revenue and a net loss for the fiscal year 2025, indicating potential challenges in its business operations [2] Financial Performance - The company achieved total operating revenue of 124.91 million yuan for the fiscal year 2025, representing a year-on-year decrease of 30.08% [2] - The net profit attributable to the parent company's shareholders was -34.30 million yuan, indicating a loss [2]

Core Viewpoint - Zhijiang Biology (688317.SH) reported a significant decline in revenue and net profit for the year 2025, primarily due to the implementation of centralized procurement policies and changes in product tax rates [1] Financial Performance - The company achieved total operating revenue of 124.91 million yuan, a decrease of 30.08% compared to the same period last year [1] - The net profit attributable to the parent company was -34.30 million yuan, representing an increase in losses by 93.16 million yuan year-on-year [1] - The net profit attributable to the parent company after deducting non-recurring gains and losses was -47.71 million yuan, which is a year-on-year increase in losses by 80.56 million yuan [1] Factors Affecting Performance - Revenue decline was attributed to the execution of centralized procurement policies leading to lower sales prices, an increase in the value-added tax rate for self-produced reagent products to 13%, and changes in product sales structure [1] - The decrease in financial income and foreign exchange gains also contributed to the operational losses [1] Strategic Response - The company is actively responding to market competition by enhancing product research and development, exploring potential opportunities, and optimizing cost reduction and efficiency improvement measures [1] - Cost control measures have shown effectiveness, with a year-on-year reduction in asset impairment losses, leading to a reduction in operational losses compared to the previous year [1]

Financial Performance - Total revenue for 2025 was CNY 12,491.36 million, a decrease of 30.08% compared to the previous year[3] - Net profit attributable to the parent company was CNY -3,430.38 million, a reduction in loss of CNY 9,315.83 million year-on-year[5] - Basic earnings per share were CNY -0.19, an improvement from CNY -0.67 in the previous year[3] Assets and Equity - Total assets at the end of the reporting period were CNY 376,367.96 million, a decrease of 0.69% from the beginning of the period[5] - Equity attributable to the parent company decreased by 7.92% to CNY 334,879.63 million[4] Revenue Drivers - The decline in revenue was primarily due to the implementation of centralized procurement policies, which led to lower sales prices[6] - The VAT rate for self-produced reagent products was adjusted to 13%, impacting revenue[7] Cost Management - The company implemented cost control measures, resulting in a reduction of asset impairment losses year-on-year[6] Strategic Focus - The company is focusing on product research and development to enhance market competitiveness[6] Data Integrity - There are no significant uncertainties affecting the accuracy of the financial data reported[10]

Core Viewpoint - The company reported a significant decline in revenue and an increase in net loss for the fiscal year 2025, primarily due to policy changes and market conditions [1] Financial Performance - The total operating revenue for 2025 was 124.91 million, a year-on-year decrease of 30.08% [1] - The net profit attributable to the parent company was -34.30 million, representing an increase in loss of 93.16 million compared to the previous year [1] - Total assets at the end of the reporting period were 376.37 million, a decrease of 0.69% from the beginning of the year [1] - The equity attributable to the parent company's owners was 334.88 million, down 7.92% from the start of the year [1] Factors Influencing Performance - The decline in revenue was mainly attributed to centralized procurement policies, tax rate adjustments, and changes in product sales structure [1] - The increase in operating losses was due to a decrease in financial income and reduced foreign exchange gains, although there was a year-on-year reduction in losses [1]

Group 1 - The core viewpoint of the announcement is that the expected related party transactions for 2026 are necessary for the company's normal operations and will not affect its independence or harm the interests of shareholders [1][2][6] - The expected amount and categories of related party transactions for 2026 are based on market prices and are essential for the company's business development [3][5] - The independent directors have reviewed and approved the related party transactions, confirming that they align with the company's interests and do not impact its independence [2][4] Group 2 - The company plans to use up to RMB 860 million of temporarily idle raised funds for cash management, ensuring it does not affect the implementation of investment projects [12][13][19] - The investment will focus on high-safety, liquidity-friendly products with a maturity of no more than 12 months, including guaranteed financial products and structured deposits [12][18] - The company aims to enhance the efficiency of fund usage and maximize shareholder returns through this cash management strategy [14][29][30]

关于上海之江生物科技股份有限公司 使用部分暂时闲置募集资金进行现金管理的核查意见 国泰海通证券股份有限公司（以下简称"国泰海通"或"保荐人"）作为上 海之江生物科技股份有限公司（以下简称"之江生物"、"公司"或"发行人"） 首次公开发行股票并在科创板上市的保荐人，根据《证券发行上市保荐业务管理 办法》《上市公司募集资金监管规则》《上海证券交易所科创板股票上市规则》 《上海证券交易所科创板上市公司自律监管指引第 1 号——规范运作》等有关法 律法规和规范性文件的要求，就之江生物使用暂时闲置募集资金进行现金管理的 事项进行了审慎核查，并发表如下核查意见: 国泰海通证券股份有限公司 一、募集资金基本情况 根据公司《首次公开发行股票并在科创板上市招股说明书》及 2025 年第一 次临时股东大会审议通过的《关于部分募投项目变更的议案》，公司调整后募集 资金投资项目基本情况如下： 单位：万元 | | | 1 | | | 总额 | 总额 | | --- | --- | --- | --- | | 1 | 体外诊断试剂生产线升级 项目 | 21,905.99 | 1,451.79 | | 2 | 分子诊断工程研发中心建 | ...